Hymecromone-SZ, tablets 200 mg 50 pcs

Pharmacotherapeutic group: choleretic remedy.

ATX code: A05AX02

Pharmacological properties

Pharmacodynamics

Bile diuretic. Increases formation and secretion of bile. It has a selective antispasmodic effect on the bile ducts and sphincter of Oddi (does not decrease peristalsis of the gastrointestinal tract (GIT) and blood pressure (BP)). It reduces bile stasis, prevents cholesterol crystallization and thereby development of cholithiasis.

Pharmacokinetics

In oral administration it is easily absorbed from digestive tract, it is weakly bound to plasma proteins. Maximal concentration in serum is reached after 2-3 hours. The elimination half-life is about 1 hour. Hymecromone is excreted by the kidneys (about 93% as glucuronate, 1.4% as sulfonate, 0.3% – unchanged).

Indications

Dyskinesia of the biliary tract and sphincter of Oddi of the hyperkinetic type, non-calculous chronic cholecystitis, cholangitis, cholelithiasis; condition after surgical interventions on the gallbladder and bile ducts. Decreased appetite, nausea, constipation, vomiting (due to bile hyposecretion).

Pharmacological effect

Pharmacotherapeutic group: choleretic agent.

ATX code: А05АХ02

Pharmacological properties

Pharmacodynamics

Choleretic drug. Increases the formation and secretion of bile. It has a selective antispasmodic effect on the bile ducts and sphincter of Oddi (does not reduce gastrointestinal motility (GIT) and blood pressure (BP)). Reduces bile stagnation, prevents cholesterol crystallization and thereby the development of cholelithiasis.

Pharmacokinetics

When taken orally, it is easily absorbed from the digestive tract and weakly binds to plasma proteins. The maximum concentration in blood serum is achieved after 2-3 hours. The half-life is approximately 1 hour. Hymecromone is excreted by the kidneys (about 93% as glucuronate, 1.4% as sulfonate, 0.3% unchanged).

Special instructions

Does not impair the secretory function of the digestive glands and intestinal absorption processes.

Impact on the ability to drive vehicles and machinery

The drug Gimecromon-SZ does not affect the ability to drive vehicles and engage in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

Active ingredient

Hymecromone

Composition

For one tablet:

active ingredient:

hymecromone – 200 mg;

excipients:

potato starch – 45.0 mg,

gelatin -3.0 mg,

sodium lauryl sulfate – 1.0 mg,

magnesium stearate – 1.0 mg.

Pregnancy

There is no data on the safety of using hymecromone during pregnancy and breastfeeding. The use of the drug Gimecromon-SZ during pregnancy and breastfeeding is permissible as prescribed by a doctor only in cases where the potential benefit to the mother outweighs the potential risk to the fetus and child.

Contraindications

Hypersensitivity.

Biliary tract obstruction, renal/liver failure, ulcerative colitis, Crohn’s disease, gastric and duodenal ulcers, hemophilia.

Children’s age up to 7 years.

Side Effects

Allergic reactions are possible; diarrhea, flatulence, abdominal pain, ulceration of the gastrointestinal mucosa, headache.

If you experience side effects listed in the instructions or they get worse, or you notice any other side effects not listed in the instructions, tell your doctor.

Interaction

Morphine weakens the effect of hymecromone.

When taken together with metoclopramide, the effect of both drugs is weakened

Enhances the effects of indirect anticoagulants.

Overdose

To date, no cases of overdose have been registered.

Storage conditions

In a place protected from light, at a temperature not exceeding 25 ° C.

Keep out of the reach of children.

Shelf life

3 years.

Do not use after expiration date.

Manufacturer

North Star NAO, Russia